FDA Grants Birelentinib Fast Track Designation for Patients With Relapsed or Refractory CLL/SLL

https://prabadinews.com/

weborders@prabadincorp.com

+1 (786)-332-3938

$FDA Grants Birelentinib Fast Track Designation for Patients With Relapsed or Refractory CLL/SLL$

Health

By AdminPrabadin - 2 months ago

Birelentinib gains FDA fast track designation, offering hope for relapsed CLL/SLL patients resistant to current BTK and BCL-2 therapies.

administrator

Related Articles